University of Michigan Establishes Elizabeth Weiser Caswell Diabetes Institute
Named for Breakthrough T1D Research Committee member Elizabeth Caswell, Institute will support diabetes research and development of life-changing diabetes therapies.
ADA’s Scientific Sessions: Day 3
The American Diabetes Association’s Scientific Sessions is here! Until June 16, scientists will present some of the most updated topics,…
Updates from the Teplizumab Trial: You’re Not Going to Believe the Results
Last year, at the American Association for Diabetes (ADA) Scientific Sessions, a drug, called teplizumab, was able to significantly delay—for…
ADA’s Scientific Sessions: Day 2
The American Diabetes Association’s Scientific Sessions is here! Until June 16, scientists will present some of the most updated topics,…
Snails—Yes, Snails—Are Helping Unlock Faster Insulins
Scientists have uncovered a potential breakthrough in developing a faster acting insulin in an unusual place: snails. Now, Breakthrough T1D-funded…
Breakthrough T1D Top Advances Over the Past Year
At Breakthrough T1D, we are committed to funding the development of new therapies to keep people with type 1 diabetes…
From the Archives: Mapping Directions for Diabetes Research
A historical account about a past initiative that would help pave the way for Breakthrough T1D’s future approach to identifying…
Dr. Jane Buckner Discusses Hydroxychloroquine T1D Prevention Study
Details about the TrialNet study, including why Hydroxychloroquine, and the status of subject participation.
Viacyte Receives Funding to Continue Developing Beta Cell Therapies
ViaCyte, a regenerative medicine company long-supported by Breakthrough T1D, today announced $27 million in financing to continue the development of…
Breakthrough T1D Partner: Huge Upsides to Telemedicine
Virtual Visits Can Transform Care and Improve Outcomes for People with T1D
